Exos Acquires Infinite Athlete and Biocore
October 30, 2025
Exos has acquired sports technology company Infinite Athlete and its subsidiary Biocore, bringing the businesses under the Exos brand to expand the company's tech-enabled human performance capabilities. The deal is backed by private equity investors BDT & MSD Partners and Madrone Capital Partners and combines Exos' coaching and workplace performance platform with Infinite Athlete's AI-driven data science and Biocore's biomechanical engineering and testing.
- Buyers
- Exos, BDT & MSD Partners, Madrone Capital Partners
- Targets
- Infinite Athlete, Biocore
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Hyperice Acquires Core to Create New Mind Technology Division
July 27, 2021
Consumer Products
Hyperice has acquired Core, a mental wellness company that produces a handheld meditation trainer and companion app, and will fold the business into a newly created Mind Technology Division. Core founder Sarah McDevitt will lead the division while co‑founder Brian Bolze joins Hyperice as Director of Software Engineering; the acquisition expands Hyperice’s product scope from physical recovery into mental wellness.
-
Core One Labs Acquires Akome Biotech
April 29, 2021
Biotechnology
Core One Labs Inc. (CSE: COOL), a Vancouver-based biotechnology company, entered into a definitive share purchase agreement to acquire all outstanding share capital of Akome Biotech Ltd. Core One will issue 3,500,000 common shares to Akome’s shareholders as consideration; the acquisition expands Core One’s psychedelic-therapeutics R&D capabilities targeting stroke, Alzheimer’s, Parkinson’s and depression.
-
Fortis Life Sciences Acquires Abcore
March 2, 2022
Biotechnology
Fortis Life Sciences has acquired Abcore, an antibody discovery platform specializing in nanobody technologies, to expand Fortis’ antibody product and service capabilities. The acquisition brings Abcore’s end-to-end discovery and custom antibody production capabilities into the Fortis platform to accelerate commercial and operational scale-up for biopharma and diagnostic customers.
-
Bain Capital Tech Opportunities Invests R$450M in Bionexo
October 15, 2021
Cloud & SaaS
Bain Capital Tech Opportunities has made a R$450 million growth investment in Bionexo, a São Paulo–headquartered healthcare cloud software and data analytics provider. The funding will be used to expand Bionexo's suite of healthcare SaaS products, accelerate AI/ML development, and pursue transformational M&A to deepen its marketplace and supply‑chain capabilities across Latin America.
-
BBI Solutions Acquires IBEX Technologies Inc.
April 8, 2024
Biotechnology
BBI Solutions OEM Limited has acquired IBEX Technologies Inc., a Montreal-based developer and manufacturer of high-precision enzymes and diagnostic solutions, with the transaction closing on April 8, 2024. The acquisition expands BBI's recombinant protein and enzyme capabilities to better serve in-vitro diagnostics (IVD) manufacturers and brings IBEX's staff and contract-manufacturing capabilities into BBI's global operations.
-
Inscripta Acquires Infinome Biosciences and Sestina Bio
January 18, 2023
Biotechnology
Inscripta, a genome engineering company based in Pleasanton, California, has acquired synthetic biology firms Infinome Biosciences and Sestina Bio to accelerate its capabilities in sustainable biomanufacturing. The acquisitions integrate Infinome's GenoScaler strain-engineering platform and Sestina's data-driven scale-up strain design to advance Inscripta's commercialization of bio-manufactured products for industrial and consumer markets.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.